Volume 155, Issue 3, Pages 705-718 (September 2018) Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia  Norah Terrault, Yi-Cheng Chen, Namiki Izumi, Zeid Kayali, Paul Mitrut, Won Young Tak, Lee F. Allen, Tarek Hassanein  Gastroenterology  Volume 155, Issue 3, Pages 705-718 (September 2018) DOI: 10.1053/j.gastro.2018.05.025 Copyright © 2018 AGA Institute Terms and Conditions

Gastroenterology 2018 155, 705-718DOI: (10.1053/j.gastro.2018.05.025) Copyright © 2018 AGA Institute Terms and Conditions

Figure 1 Overview of the phase 3 studies ADAPT-1 and ADAPT-2 (A) Study design. aVisit 3 occurred on day 4 (±1 day) during the treatment period. (B) Patient disposition. PLT, platelet count; R, ratio. Gastroenterology 2018 155, 705-718DOI: (10.1053/j.gastro.2018.05.025) Copyright © 2018 AGA Institute Terms and Conditions

Figure 2 ADAPT-1 and ADAPT-2 efficacy endpoints. (A) Proportion of patients not requiring a platelet transfusion or any rescue procedure for bleeding. (B) Proportion of patients who achieved platelet counts ≥ 50 × 109/L on procedure day. (C) Magnitude of change in platelet count from baseline to procedure day. Full analysis set. Difference in change from baseline of platelet count for avatrombopag vs placebo within each cohort was based on Hodges-Lehmann estimation. Gastroenterology 2018 155, 705-718DOI: (10.1053/j.gastro.2018.05.025) Copyright © 2018 AGA Institute Terms and Conditions

Figure 3 Mean platelet counts by treatment group and visit day. (A) ADAPT-1. (B) ADAPT-2. Gastroenterology 2018 155, 705-718DOI: (10.1053/j.gastro.2018.05.025) Copyright © 2018 AGA Institute Terms and Conditions